BSD Medical Closes Previously Announced $5 Million Registered Direct Offering of Common Stock and Warrants

  BSD Medical Closes Previously Announced $5 Million Registered Direct
  Offering of Common Stock and Warrants

           Proceeds to help fund company’s international expansion

Business Wire

SALT LAKE CITY -- April 15, 2013

BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a
leading provider of medical systems that utilize heat therapy to treat cancer,
today announced that the required closing of its previously announced $5.0
million registered direct offering of common stock and warrants occurred.

Proceeds will be used for general working capital purposes, including to
support BSD’s international expansion associated with its just announced
master distribution agreement of its MicroThermX^® products in 100 countries,
including Europe, Western Asia and Northern Africa and for the Company’s
recently signed distribution agreement for its hyperthermia products in
Taiwan.

As previously disclosed, the company sold 4,065,042 shares of its common stock
at $1.23 per share to two institutional investors in the registered direct
offering. In addition, warrants to purchase 3,048,782 shares of common stock
in the aggregate were issued to the investors. The warrants are exercisable
beginning six months and one day after April 12, 2013, expire 5 years after
becoming exercisable, and have an exercise price of $1.65 per share. As
previously disclosed, the transaction was required to close on or before April
12, 2013. Roth Capital Partners served as the placement agent for the
offering.

The shares of common stock and warrants described above were offered pursuant
to an effective shelf registration statement as filed with the Securities and
Exchange Commission. A prospectus supplement relating to the offering was
filed with the Securities and Exchange Commission on April 9, 2013. This press
release does not constitute an offer to sell or the solicitation of an offer
to buy, and these securities cannot be sold in any state in which this offer,
solicitation, or sale would be unlawful prior to registration or qualification
under the securities laws of any such state. Any offer will be made only by
means of a prospectus, including a prospectus supplement, forming a part of
the effective registration statement. Copies of the final prospectus
supplement and accompanying base prospectus can be obtained from Roth Capital
Partners at 888 San Clemente Drive, Newport Beach, CA 92660, attention: Equity
Capital Markets or 800-678-9147 or rothecm@roth.com.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy, which is delivered
using focused radiofrequency (RF) and microwave energy. BSD’s product lines
include both hyperthermia and ablation treatment systems. BSD’s hyperthermia
cancer treatment systems, which have been in use for several years in the
United States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to employ precision-guided microwave energy to ablate
(destroy) soft tissue. The Company has developed extensive intellectual
property, multiple products in the market and established distribution in the
United States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States, Europe and
China. For further information visit BSD Medical's website at
www.BSDMedical.com.

This press release may be deemed to contain forward-looking statements, which
are subject to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, including the expected use of proceeds relating to the
recently completed offering. Readers are cautioned that these forward-looking
statements are only predictions and may differ materially from actual future
events or results due to a variety of factors, including, among other things,
the demand for the Company’s products, the ability of the Company to produce
the products to meet the demand, global economic conditions and uncertainties
in the geopolitical environment and other risk factors set forth in the
Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking
statements in this release are based on limited information currently
available to the Company, which is subject to change, and the Company will not
necessarily update the information.

Contact:

BSD Medical Corporation
William (Bill) S. Barth, 801-972-5555
fax: 801-972-5930
investor@bsdmc.com
 
Press spacebar to pause and continue. Press esc to stop.